Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement

Cancer Research
Alice DallatomasinaAngelo Corti

Abstract

The unbalanced production of pro- and antiangiogenic factors in tumors can lead to aberrant vasculature morphology, angiogenesis, and disease progression. In this study, we report that disease progression in various murine models of solid tumors is associated with increased cleavage of full-length chromogranin A (CgA), a circulating vasoregulatory neurosecretory protein. Cleavage of CgA led to the exposure of the highly conserved PGPQLR site, which corresponds to residues 368-373 of human CgA1-373, a fragment that has proangiogenic activity. Antibodies against this site, unable to bind full-length CgA, inhibited angiogenesis and reduced tumor perfusion and growth. The PGPQLR sequence of the fragment, but not of the precursor, bound the VEGF-binding site of neuropilin-1; the C-terminal arginine (R373) of the sequence was crucial for binding. The proangiogenic activity of the CgA1-373 was blocked by anti-neuropilin-1 antibodies as well as by nicotinic acetylcholine receptor antagonists, suggesting that these receptors, in addition to neuropilin-1, play a role in the proangiogenic activity of CgA1-373. The R373 residue was enzymatically removed in plasma, causing loss of neuropilin-1 binding and gain of antiangiogenic activity. Th...Continue Reading

References

Jan 22, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Elisabetta FerreroAngelo Corti
Dec 24, 2005·The Journal of Biological Chemistry·Mathew A von WronskiAdrian D Nunn
Mar 31, 2007·Nature Reviews. Drug Discovery·Judah Folkman
Jun 15, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Daniela BelloniElisabetta Ferrero
Aug 25, 2007·Cellular and Molecular Life Sciences : CMLS·K B HelleB Tota
Jan 2, 2009·Leukemia Research·Domenico Ribatti
Feb 24, 2009·Trends in Cardiovascular Medicine·John P Cooke, Yohannes T Ghebremariam
Apr 30, 2009·The International Journal of Biochemistry & Cell Biology·Hugo R AriasShaker A Mousa
Oct 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Tambet TeesaluErkki Ruoslahti
Feb 2, 2010·Regulatory Peptides·Sushil K MahataDaniel T O'Connor
Nov 17, 2010·Cellular and Molecular Neurobiology·Angelo Corti
Nov 26, 2010·Ultrasound in Medicine & Biology·A NeedlesF S Foster
Jul 13, 2011·Journal of Cellular Biochemistry·Victoria B Ayala PeñaFrancisco J Barrantes
Aug 10, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Lorenzo VeschiniElisabetta Ferrero
Feb 10, 2012·The Journal of Biological Chemistry·Matthew W ParkerCraig W Vander Kooi
Jul 28, 2012·Current Medicinal Chemistry·A Corti, E Ferrero
Jul 23, 2013·Journal of Molecular Biology·Matthew W ParkerCraig W Vander Kooi
Aug 30, 2013·Frontiers in Oncology·Tambet TeesaluErkki Ruoslahti
Feb 14, 2014·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·Alice PleinChristiana Ruhrberg
Oct 10, 2014·Cellular and Molecular Life Sciences : CMLS·Karen B Helle, Angelo Corti
Sep 30, 2016·Oncotarget·Flavio CurnisAngelo Corti
Apr 27, 2017·Progress in Neurobiology·Josef TrogerKaren B Helle
Sep 1, 2017·Cellular and Molecular Life Sciences : CMLS·Wei LiHong Tian

❮ Previous
Next ❯

Citations

Oct 8, 2019·Annals of the New York Academy of Sciences·Sushil K Mahata, Angelo Corti
Apr 4, 2020·Journal of Molecular Histology·Ho Seok SeoHan Hong Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.